Will PIONEER AF-PCI change my practice?

Christian Ukena, Sergio Leonardi, Tullio Palmerini, Alexandra Lansky, Gilles Montalescot, Marco Valgimigli

Research output: Contribution to journalArticle

Abstract

ARGUMENTS FOR A CHANGE IN PRACTICE - Single antiplatelet therapy in combination with reduced oral anticoagulation reduces the rate of bleeding events in comparison to triple therapy after PCI in patients with atrial fibrillation (PIONEER AF-PCI, WOEST). ARGUMENTS AGAINST A CHANGE IN PRACTICE - Current trials are underpowered to assess the risk of ischaemic events adequately, especially stent thrombosis. - Differences in bleeding events are mainly driven by minor bleedings. - Patients must be responders to the agent used in case of single antiplatelet therapy in combination with oral anticoagulation. Results of further ongoing trials (REDUAL-PCI, ENTRUSTAF-PCI, AUGUSTUS) are expected soon.

Original languageEnglish
Pages (from-to)e609-e612
JournalEuroIntervention
Volume13
Issue number5
DOIs
Publication statusPublished - Aug 1 2017

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Will PIONEER AF-PCI change my practice?'. Together they form a unique fingerprint.

  • Cite this

    Ukena, C., Leonardi, S., Palmerini, T., Lansky, A., Montalescot, G., & Valgimigli, M. (2017). Will PIONEER AF-PCI change my practice? EuroIntervention, 13(5), e609-e612. https://doi.org/10.4244/EIJV13I5A95